Case Study: Bringing a Sports-Medicine Fixation Line Through INVIMA Registration

The line was ready everywhere except Colombia. A manufacturer of soft-tissue fixation implants — suture anchors in metal, PEEK and all-suture constructions, interference screws, a meniscal repair system, an artificial ligament — held a CE mark, had surgeons asking for the products in Bogotá and Medellín, and had a distributor with a proposal: give us the paperwork, we'll register it ourselves, it won't cost you anything.

That offer is where this case study starts, because what the manufacturer decided in that moment mattered more than anything filed afterwards.

The offer that would have cost the most

The distributor's proposal was genuine, and common. In Colombia a foreign manufacturer cannot hold its own registro sanitario; two local parties have to exist first — a Legal Representative to file and answer INVIMA, and a licensed importer holding a CCAA, the Certificate of Storage and Conditioning Capacity, whose name goes on the registration itself. A distributor volunteering for both roles removes two problems in one conversation.

It also takes ownership of the market. The registration is issued to its holder. Had the sales channel held it, every later commercial negotiation — margins, a second distributor, an exit — would have happened with the manufacturer's market access sitting on the other side of the table.

The manufacturer declined, and the roles were split instead: our Colombian entity took the registro as independent titular, and its Bogotá operation — which already held INVIMA's CCAA facility licence — was named importer of record. That second part deserves a sentence, because it is the step that cannot be improvised: a CCAA certifies a physical warehouse operation, with documented storage, conditioning and vigilance practices, and it cannot be conjured in the weeks between an approval and a first shipment. It was already standing, so it never appeared on the critical path. The in-country representation model this created — regulatory roles independent of the sales channel — is the same one we run as registration holder in other markets.

Classification: the afternoon the calendar was decided

The next decision looked clerical and wasn't. The team's first instinct was to reason from their US file — Class II there, so presumably mid-tier here. That number meant nothing in Bogotá: Colombia classifies devices under Decree 4725/2005, and the scheme follows European MDD logic, not the US system — so it was the CE rationale that carried most of the way. Mapped against the Colombian rules on our INVIMA classification page:

The implants went to Class IIb. A suture anchor holding soft tissue to bone, an interference screw fixing a graft in a tunnel, a meniscal implant, an artificial ligament — surgically invasive, intended to stay in the body beyond 30 days, long-term implantable. Class IIb, all of them.

The arthroscopic blades and burrs went to Class IIa. Surgically invasive but transient — in, working, out within the procedure.

On paper, one class apart. In the calendar, two different markets. Class I and IIa devices clear on Colombia's automatic pathway: authorization follows a complete application with no prior technical review — INVIMA's published term is two working days from filing. Class IIb and III go through controlled review, where INVIMA examines the technical file before granting anything — the term Decree 4725 sets for that review is 90 working days, and the launch model the manufacturer arrived with had trusted that number. The practical range our Colombia guidance publishes is 6 to 8 months, and the program was rebuilt around that reality from this afternoon onward. (Those are market-level figures from our published guidance; grant dates in a public registry say as much about queue conditions as about any one dossier, so we do not publish timings from our own filings.)

One more decision was taken at the same desk: grouping. Colombia allows several products under one registration where risk class, indications for use and manufacturer align — which is the difference between registering an anchor line and registering every diameter and material in it separately. The grouping map was drawn before a single page of dossier existed.

What the file review caught

The dossier came together in three to four weeks — the range our guidance gives for preparation and filing — and mostly without drama: a Certificate of Free Sale from a reference market, technical documentation, risk files, test reports, everything rendered in Spanish.

The catch was the quality certificate. ISO 13485 is genuinely required at Class IIb, not merely recommended, and the pre-filing review turned up a scope problem of the kind that recurs constantly in this work: the certificate named the legal manufacturer, but its scope did not cleanly cover a second manufacturing site involved in the implant line. Filed as it stood, that is a deficiency letter months into a controlled review. Caught before filing, it was a certificate reissue — annoying, cheap, and invisible in the final timeline.

The Spanish labeling was the other piece settled early, because Colombia's rules reward it: as our labeling page sets out, the original label can stay, with a supplemental Spanish label carrying the device name, manufacturer, importer and registration number. Two details were treated with more respect than they usually get — the sterile and single use legends on the physical label, and the fact that the label names the importer, which quietly means a change of importer later is a labeling change too. GMDN terms were locked at the same time so the dossier, label and later vigilance filings would describe the products identically.

Two lanes, one line

Then the filings split, deliberately.

The Class IIb implants — the products the revenue plan actually depended on — went into controlled review first, because nothing shortens that queue and every week of delay at the start is a week at the end.

The Class IIa blades and burrs went in on the automatic pathway at the same time, cleared on the scale of days, and became the advance party. The first containers of instruments did the unglamorous work: they exercised the import registration, the customs path, the supplemental labels and the CCAA warehouse while the implants were still under review. By the time the implant registrations issued, importing into Colombia was a routine the operation had already run — the first controlled-pathway shipment was not also the first shipment of any kind.

Colombia adds one quiet incentive to get this order right: under Decree 4725, the product must be commercialized within 36 months of the granting act — and a registration that isn't is cancelled automatically, no discretion involved. A registration secured ahead of its commercial channel is an asset with a clock on it.

The rule that changed under the program

Midway through the engagement, a rule that had been phasing in for years arrived at its final deadline. Resolution 1405 of 2022 requires every registration holder to implement UDI-DI codes from a recognized issuing agency and file a semantic report on each device through INVIMA's platform; its last deferred deadline — 8 February 2026, covering Class I, IIa and low-risk IVD records — has now passed, putting every class in scope.

The interesting part was watching where that duty actually lands. The codes come from the manufacturer's issuing agency — GS1, in this case. The semantic report is the titular's to file. A duty split across two parties is a duty that goes unperformed when the parties assume it belongs to the other — which is precisely what a casual distributor-held arrangement leaves undefined, and what a written division of roles settles in advance. The line's records went into the platform as the deadline required, new filings now arrive carrying codes from the start, and the next rule change will be absorbed from the same position.

The outcome, and the bill

The registrations are in force — implants through controlled review, instruments via the automatic pathway — with our entity as titular and importer of record, ten years of validity on the device registrations, renewals due three months before expiry, and the 36-month commercialization clock long since satisfied by the instrument shipments.

Three post-approval realities surprised the manufacturer more than the approval itself. The quarterly vigilance report is due even when there is nothing to report — a nil report is still a filing. A change of importer is a notification handled in days, but a change touching safety, effectiveness, design or chemical composition is a new registration, which reshaped how the team scheduled a planned product revision. And the launch campaign got a regulatory read of its own: advertising claims in Colombia must be supported by scientific evidence and cannot exaggerate benefit to the patient — with the Legal Representative liable for them. The products are where the surgeons who asked for them are.

What a line shaped like this one costs, at the published rates:

INVIMA government fees (per product)

Government fees only; rates as published, last verified January 2026, subject to change.

Our flat annual fee

The flat fee covers dossier preparation and submission, in-country representation, translation, post-approval modifications, changing or adding importers, CCAA licensing and post-market support; INVIMA fees, certified translations and non-English source translations are separate. A three-year contract locks the rates; catalogs of 11+ are quoted individually.

Priced at those rates, a catalog shaped like this one — four Class IIa instruments on the automatic pathway, three Class IIb implant families on controlled review — comes to $11,000 per year in service fees plus roughly USD 6,900 in one-time government fees: a first-year total near USD 17,900, with the government portion not recurring. Price your own mix in the fee calculator.

Doing this for your product line

The order this engagement followed is the order that works: settle who holds the registro before anything is filed, confirm classification against Decree 4725 rather than assuming a home-market class carries over, file the long-pole products first and let the fast-lane products exercise the channel, get the ISO 13485 scope and the Spanish label right before submission rather than after a deficiency letter, and treat post-market obligations — renewals, modifications, vigilance, UDI — as part of the same engagement, not an afterthought.

Start with the Colombia market page, see how the same decisions played out under ANVISA in our Brazil endoscope case study, or talk to our team about your line.